

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	CXC chemokine receptor 4 (CXCR4; NPY3R)	<p>A study in mice suggests that CXCR4 antagonists may increase the efficacy of vascular disrupting agents in treating cancer. In a mouse model of breast cancer, treatment with CA4P, a tumor vascular disrupting agent, in combination with AMD3100, a synthetic CXCR4 antagonist, led to less tumor growth than treatment with CA4P alone. Next steps could include testing the combination in additional preclinical cancer models.</p> <p>OxiGene Inc.'s Zybrestat fosbretabulin (CA4P) is in clinical trials for various cancers.</p> <p>Genzyme Corp.'s Plerixafor (AMD3100) is marketed for multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL).</p> <p>SciBX 4(16); doi:10.1038/scibx.2011.453 Published online April 21, 2011</p>	Patent and licensing status unavailable	<p>Welford, A.F. <i>et al. J. Clin. Invest.</i>; published online April 1, 2011; doi:10.1172/JCI44562</p> <p>Contact: Claire E. Lewis, The University of Sheffield Medical School, Sheffield, U.K. e-mail: claire.lewis@sheffield.ac.uk</p>